10-Q: Therapeutic Solutions International Reports Mixed Results in Q2 2024 Amidst Ongoing Development

Therapeutic Solutions International reported a net loss for the second quarter of 2024, alongside a decrease in revenue, while continuing to advance its research and development programs.

Summary

• Therapeutic Solutions International (TSOI) reported a net loss of $390,046 for the three months ended June 30, 2024, a decrease from the $562,400 loss in the same period of 2023.
• The company's net loss for the six months ended June 30, 2024, was $975,187, compared to a net loss of $1,140,281 for the same period in 2023.
• Net sales decreased to $20,005 for the three months ended June 30, 2024, from $26,308 in 2023, and to $41,819 for the six months ended June 30, 2024, from $49,431 in 2023.
• Operating expenses for the three-month period decreased to $417,316 in 2024 from $558,115 in 2023, while operating expenses for the six-month period increased to $1,104,881 in 2024 from $1,002,639 in 2023.
• The company's accumulated deficit stands at approximately $21.3 million as of June 30, 2024, with a working capital deficit of approximately $1.1 million.
• TSOI is focused on immune modulation and developing treatments for various diseases, including cancer, schizophrenia, and traumatic brain injury.
• The company has a nutraceutical division, with QuadraMune as its flagship product, and a cellular division focused on stem cell therapies.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive developments in reducing losses and advancing research, but significant concerns remain regarding the company's financial stability, revenue generation, and internal controls. The company's reliance on future capital raises and the risks associated with its penny stock status contribute to a negative sentiment.

Positives

• The company's net loss decreased for both the three and six-month periods compared to the previous year.
• Operating expenses decreased for the three-month period.
• Research and development expenses decreased significantly, which may indicate a shift towards commercialization or more efficient spending.
• TSOI continues to expand its intellectual property portfolio with numerous patent filings.
• The company is actively pursuing clinical trials for its various therapies.

Negatives

• The company experienced a decrease in net sales for both the three and six-month periods.
• Operating expenses increased for the six-month period.
• The company has a significant accumulated deficit and a working capital deficit, raising concerns about its financial stability.
• The company's disclosure controls and procedures were deemed not operating effectively.
• Material weaknesses were identified in the company's internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.
• There is no guarantee that the company will receive the required financing or that it will be available on acceptable terms.
• The company's stock is currently classified as a penny stock, which may lead to volatility and illiquidity.
• The company is dependent on third-party manufacturers, which could pose supply chain risks.
• The company faces potential product liability claims and risks related to protecting its intellectual property.
• The company has a limited operating history in its new business model and limited experience introducing new products.

Future Outlook

The company intends to finance operating costs through existing financial resources and may raise additional capital through equity offerings, debt financings, collaborations, and/or licensing arrangements. If adequate funds are not available, the company may be required to delay, reduce the scope of, or curtail its operations.

Management Comments

• Management does not expect existing cash as of June 30, 2024, to be sufficient to fund the Company's operations for at least twelve months from the issuance date of these financial statements.
• Management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.
• Management is committed to meeting or exceeding the standards set by the FDA.

Industry Context

The company operates in the biotechnology and nutraceutical industries, which are characterized by high research and development costs, regulatory hurdles, and competition. The company's focus on immune modulation and stem cell therapies aligns with current trends in regenerative medicine and personalized healthcare. The company's nutraceutical division is also positioned to capitalize on the growing consumer interest in health and wellness products.

Comparison to Industry Standards

• The company's financial performance, particularly its net losses and working capital deficit, is not uncommon for early-stage biotechnology companies that are heavily investing in research and development.
• Compared to established pharmaceutical companies, TSOI's revenue is significantly lower, reflecting its early stage of commercialization.
• Companies like BioNTech and Moderna, which have successfully developed and commercialized mRNA-based therapies, serve as examples of the potential for high growth and profitability in the biotechnology sector, but also highlight the risks and challenges involved.
• TSOI's focus on stem cell therapies is comparable to companies like Mesoblast and Athersys, which are also developing cell-based therapies for various diseases, but these companies have significantly more funding and are further along in clinical development.
• The nutraceutical market is highly competitive, with numerous companies offering similar products. TSOI's QuadraMune product needs to differentiate itself through clinical evidence and effective marketing to gain market share.
• The company's patent portfolio is a key asset, but the value of these patents will depend on their successful commercialization and protection from infringement.

Legal Proceedings

• TSOI has filed suit against anonymous online posters for defamation.
• Kyle Shepard sued the Veltmeyer Institute, Dr. James Veltmeyer, TSOI, and Dr. Thomas Ichim for fraud, breach of fiduciary duty, conversion, and intentional interference with contracts.

Related Party Transactions

• The company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $714,558 and $692,284 at June 30, 2024 and 2023 respectively.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost-cutting measures if the company's financial situation does not improve.
• Customers may be impacted by potential delays in product development or availability.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.
• The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.

Next Steps

• The company intends to continue to raise additional capital.
• The company plans to continue its research and development programs.
• The company will continue to pursue clinical trials for its various therapies.
• The company will continue to monitor and address the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

immune modulation, stem cell therapy, nutraceuticals, QuadraMune, JadiCell, cancer immunotherapy, schizophrenia, traumatic brain injury, clinical trials, patents, financial results, convertible notes